AstraZeneca (China): Promoting Social Innovation with Holistic Disease Management Solutions throughout the Patient Journey

Social Sciences

• Cardiovascular Disease 14%
• China 100%
• Chinese 14%
• Digitization 14%
• Diseases 100%
• Drugs 57%
• Financial Resources 14%
• Human Resources 14%
• Industrial Sector 14%
• Medical Treatment 14%
• Research and Development 14%
• Sales 71%
• Social Benefit 14%
• Social Innovation 100%
• Social Responsibility 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Budesonide 50%
• Cardiovascular Disease 50%
• Combination Therapy 50%
• Disease 100%
• Gastroenterology 50%
• Nebulizer 50%
• Prostate Cancer 50%
• Respiratory Tract Disease 50%
• Thorax Pain 50%

Economics, Econometrics and Finance

• Human Resources 50%
• Return on Investment 50%
• Social Innovation 100%
• Social Responsibility 50%
• Specific Industry 50%